Binding and Pharmacokinetics of the Sodium Channel Blocking Toxins (Saxitoxin and the Tetrodotoxins)

2017 ◽  
Vol 17 (4) ◽  
pp. 320-327 ◽  
Author(s):  
V. Pratheepa ◽  
Vitor Vasconcelos
2020 ◽  
Vol 27 ◽  
Author(s):  
Alessia Catalano ◽  
Carlo Franchini ◽  
Alessia Carocci

: Mexiletine is an antiarrhythmic drug belonging to IB class, acting as sodium channel blocker. Besides its well-known activity on arrhythmias, its usefulness in the treatment of myotonia, myotonic distrophy and amyotrophic lateral sclerosis is now widely recognized. Nevertheless, it has been retired from the market in several countries because of its undesired effects. Thus, several papers were reported in the last years about analogues and homologues of mexiletine being endowed with a wider therapeutic ratio and a more selectivity of action. Some of them showed sodium channel blocking activity higher than the parent compound. It is noteworthy that mexiletine is used in therapy as a racemate even though a difference in the activities of the two enantiomers were widely demonstrated, with (–)-(R)-enantiomer being more active: this finding led several research groups to study mexiletine and its analogues and homologues in their optically active forms. This review summarizes the different synthetic routes used to obtain these compounds. They could represent an interesting starting point to new mexiletine-like compounds without common side effects related to the use of mexiletine.


Author(s):  
Stacey Peters ◽  
Bryony A. Thompson ◽  
Mark Perrin ◽  
Paul James ◽  
Dominica Zentner ◽  
...  

Background: Variants in the SCN5A gene, that encodes the cardiac sodium channel, Nav1.5, are associated with a highly arrhythmogenic form of dilated cardiomyopathy (DCM). Our aim was to review the phenotypes, natural history, functional effects, and treatment outcomes of DCM-associated rare SCN5A variants. Methods: A systematic review of reported DCM-associated rare SCN5A variants was undertaken using PubMed and Embase. Results: Eighteen SCN5A rare variants in 29 families with DCM (173 affected individuals) were identified. Eleven variants had undergone experimental evaluation, with 7 of these resulting in increased sustained current flow during the action potential (eg, increased window current) and at resting membrane potentials (eg, creation of a new gating pore current). These variants were located in transmembrane voltage-sensing domains and had a consistent phenotype characterized by frequent multifocal narrow and broad complex ventricular premature beats (VPB; 72% of affected relatives), ventricular arrhythmias (33%), atrial arrhythmias (32%), sudden cardiac death (13%), and DCM (56%). This VPB-predominant phenotype was not seen with 1 variant that increased late sodium current, or with variants that reduced peak current density or had mixed effects. In the latter groups, affected individuals mainly showed sinus node dysfunction, conduction defects, and atrial arrhythmias, with infrequent VPB and VA. DCM did not occur in the absence of arrhythmias for any variant. Twelve studies (23 total patients) reported treatment success in the VPB-predominant cardiomyopathy using sodium channel-blocking drug therapy. Conclusions: SCN5A variants can present with a diverse spectrum of primary arrhythmic features. A majority of DCM-associated variants cause a multifocal VPB-predominant cardiomyopathy that is reversible with sodium channel blocking drug therapy. Early recognition of the distinctive phenotype and prompt genetic testing to identify variant carriers are needed. Our findings have implications for interpretation and management of SCN5A variants found in DCM patients with and without arrhythmias.


2013 ◽  
Vol 4 (3) ◽  
pp. 463-474 ◽  
Author(s):  
Ki Duk Park ◽  
Xiao-Fang Yang ◽  
Hyosung Lee ◽  
Erik T. Dustrude ◽  
Yuying Wang ◽  
...  

2003 ◽  
Vol 86 (3) ◽  
pp. 540-543 ◽  
Author(s):  
Ronald L Manger ◽  
Linda S Leja ◽  
Sue Y Lee ◽  
James M Hungerford ◽  
Mary Ann Kirkpatrick ◽  
...  

Abstract Although cytotoxicity assays provide several advantages over mouse bioassays, sodium channel-blocking marine toxins, such as those associated with paralytic shellfish poison (PSP), require prolonged incubation periods of 24–48 h. This is in marked contrast to in vitro detection of sodium channel-enhancing marine toxins such as ciguatoxins or brevetoxins which can be accomplished in as few as 4–6 h. We developed a modified PSP cell bioassay that is as rapid as in vitro methods for sodium channel-enhancing toxins. The cell bioassay is based on a saxitoxin-dependent antagonism of the rapid in vitro effects of brevetoxin or ciguatoxin. Comparative analysis of naturally incurred PSP residues by both antagonism cell bioassay and the mouse bioassay demonstrated significant correlation. The simplicity, sensitivity, and enhanced kinetics of the new antagonism cell bioassay format provide the basis for development of a practical alternative to conventional mouse testing for PSP.


2004 ◽  
Vol 47 (1) ◽  
pp. 146-155 ◽  
Author(s):  
J.K. Callaway ◽  
M. Castillo-Melendez ◽  
S.F. Giardina ◽  
E.K. Krstew ◽  
P.M. Beart ◽  
...  

Biochemistry ◽  
1995 ◽  
Vol 34 (27) ◽  
pp. 8649-8656 ◽  
Author(s):  
Michael Fainzilber ◽  
Takemichi Nakamura ◽  
Ariel Gaathon ◽  
Johannes C. Lodder ◽  
Karel S. Kits ◽  
...  

2016 ◽  
Vol 135 (4) ◽  
pp. 434-441 ◽  
Author(s):  
M. Baulac ◽  
W. Byrnes ◽  
P. Williams ◽  
S. Borghs ◽  
E. Webster ◽  
...  

1998 ◽  
Vol 9 (1) ◽  
pp. S52
Author(s):  
W. A. Kozak ◽  
M. A. Cervini ◽  
R. A. McArthur ◽  
C. Post ◽  
R Salvati

Sign in / Sign up

Export Citation Format

Share Document